Sihuan Pharmaceutical Holdings Group Ltd. (HK:0460)

:0460

0460

Sihuan Pharmaceutical Holdings Group

RESEARCH TOOLSreports

Want to see HK:0460 full AI Analyst Report?

Sihuan Pharmaceutical Holdings Group (0460) Price & Analysis

1 Followers

0460 Stock Chart & Stats

HK$1.32

HK$0.00(0.00%)

At close: Jan 09 4:00 PM EST

HK$1.32

HK$0.00(0.00%)

Day’s Range― - ―

52-Week RangeHK$0.88 - HK$1.92

Previous CloseN/A

Volume8.01M

Average Volume (3M)37.54M

Market Cap

HK$8.77B

Enterprise ValueHK$4.11B

Total Cash (Recent Filing)HK$4.10B

Total Debt (Recent Filing)HK$1.01B

Price to Earnings (P/E)40.3

Beta1.05

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.87%

Share Statistics

EPS (TTM)0.02

Shares Outstanding9,329,999,000

10 Day Avg. Volume24,963,024

30 Day Avg. Volume37,542,935

Financial Highlights & Ratios

PEG Ratio-0.30

Price to Book (P/B)1.72

Price to Sales (P/S)3.85

P/FCF Ratio-46.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$1.75

Price Target Upside32.58% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)0.07

Revenue Forecast (FY)HK$3.56B

Bulls Say, Bears Say

Bulls Say

Revenue RecoveryA 21.6% revenue rebound and return to positive net income in 2025 indicate restored commercial execution and demand for core products. This recovery improves long-term cash generation potential if sustained and supports reinvestment in sales coverage and R&D to deepen market penetration.

High Gross MarginsSustained gross margins around 65–70% reflect pricing power and a favorable product mix (branded or specialty drugs). High gross margins provide durable earnings leverage, help absorb SG&A or R&D investment, and create a buffer against raw-material or input-cost variability.

Conservative LeverageA low and improving debt-to-equity (~0.16) gives the company balance-sheet flexibility to fund operations or strategic investments. Manageable leverage reduces refinancing risk during cash-flow stress and supports resilience against industry cyclicality or regulatory shifts in China.

Bears Say

Weak Cash GenerationNegative operating cash flow and deeply negative free cash flow in 2025, despite reported net income, indicate poor quality of earnings. Persistent cash conversion problems constrain the company's ability to self-fund capex, R&D, or working-capital needs without external financing.

Inconsistent Free Cash FlowMulti-year inconsistent free cash flow (several negative years) complicates capital allocation and long-term planning. Irregular FCF raises uncertainty over the firm's capacity to sustain investments, dividends, or deleveraging, increasing execution and liquidity risk for investors.

Earnings Volatility And Low ROEA history of very large losses and negative margins followed by low ROE (~3% in 2025) signals earnings volatility and modest returns on equity. This undermines confidence in sustainable profitability and indicates management still faces challenges translating assets into consistent shareholder value.

Sihuan Pharmaceutical Holdings Group News

Sihuan Pharmaceutical Buys Shares for Award Scheme as Medical Aesthetics Surges

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an update. Sihuan Pharmaceutical Holdings Group has executed a...

9d ago

Sihuan Pharmaceutical Buys Shares for Award Scheme as Medical Aesthetics Drives Profitable Growth

An announcement from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) is now available. Sihuan Pharmaceutical’s trustee has purchased...

14d ago

Sihuan Pharmaceutical Sets 2026 AGM to Approve FY2025 Results, Dividend and Share Issuance Mandate

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an announcement. Sihuan Pharmaceutical Holdings Group has called its...

15d ago

Sihuan Pharmaceutical Forms AI-Driven Medical Aesthetics JV with dProtein

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an update. Sihuan Pharmaceutical has signed a cooperation agreement...

20d ago

Sihuan Pharma Buys Shares for Award Scheme as Medical Aesthetics Drives Profit Turnaround

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) just unveiled an update. Sihuan Pharmaceutical Holdings Group has instructed the...

21d ago

Sihuan Pharmaceutical Launches Share Buyback as Medical Aesthetics Surge Drives Return to Profit

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an update. Sihuan Pharmaceutical Holdings Group has announced a...

30d ago

Sihuan Pharma Launches Share Buyback as Medical Aesthetics Surges

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an update. Sihuan Pharmaceutical Holdings Group has strengthened its...

1M ago

Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong

The latest update is out from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ). Sihuan Pharmaceutical announced that its...

1M ago

Sihuan Pharma Uses Share Award Buy to Back Profitable Growth in Aesthetics and Biopharma

An update from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) is now available. Sihuan Pharmaceutical has reported that...

2M ago

Sihuan’s NG-350A Shows Promising Early Results in Rectal Cancer Trial

An announcement from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) is now available. Sihuan Pharmaceutical announced that preliminary...

2M ago

0460 FAQ

What was Sihuan Pharmaceutical Holdings Group Ltd.’s price range in the past 12 months?

Sihuan Pharmaceutical Holdings Group Ltd. lowest stock price was HK$0.88 and its highest was HK$1.92 in the past 12 months.

What is Sihuan Pharmaceutical Holdings Group Ltd.’s market cap?

Sihuan Pharmaceutical Holdings Group Ltd.’s market cap is HK$8.77B.

When is Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date?

Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 76 days.

How were Sihuan Pharmaceutical Holdings Group Ltd.’s earnings last quarter?

Sihuan Pharmaceutical Holdings Group Ltd. released its earnings results on Mar 31, 2026. The company reported HK$0.009 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.009.

Is Sihuan Pharmaceutical Holdings Group Ltd. overvalued?

According to Wall Street analysts Sihuan Pharmaceutical Holdings Group Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sihuan Pharmaceutical Holdings Group Ltd. pay dividends?

Sihuan Pharmaceutical Holdings Group Ltd. pays a Annually dividend of HK$0.011 which represents an annual dividend yield of 0.87%. See more information on Sihuan Pharmaceutical Holdings Group Ltd. dividends here

What is Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate?

Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sihuan Pharmaceutical Holdings Group Ltd. have?

Sihuan Pharmaceutical Holdings Group Ltd. has 9,329,999,000 shares outstanding.

What happened to Sihuan Pharmaceutical Holdings Group Ltd.’s price movement after its last earnings report?

Sihuan Pharmaceutical Holdings Group Ltd. reported an EPS of HK$0.009 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.493%.

Which hedge fund is a major shareholder of Sihuan Pharmaceutical Holdings Group Ltd.?

Currently, no hedge funds are holding shares in HK:0460

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sihuan Pharmaceutical Holdings Group Stock Smart Score

Outperform

Analyst Consensus

Moderate Buy

Average Price Target:
HK$1.75 (32.58% Upside)

Technicals

Fundamentals

Return on Equity

3.51%

Trailing 12-Months

Asset Growth

15.37%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharmaceutical Holdings Group Ltd. functions as an investment holding company, primarily dedicated to the research, development, manufacturing, marketing, and distribution of pharmaceutical products across the People's Republic of China. Its drug portfolio encompasses a range of therapeutic areas, including oncology, metabolic disorders, and digestive system ailments. The company also diversifies its operations through investments in and sales of medical aesthetic products, the production of medical devices, property investments, undertaking medical construction initiatives, and preparing for new pharmaceutical manufacturing projects. Additionally, it delivers various services, such as informational support, general hospital services, hospital management, biotechnology promotion, and research and development in medical aesthetics. Founded in 2001, the firm is headquartered in Wanchai, Hong Kong.

Sihuan Pharmaceutical Holdings Group (0460) Earnings & Revenues

Historic Earnings Reports

0460 Stock 12 Month Forecast

Average Price Target

HK$1.75

▲(32.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"HK$0","1":"HK$1","2":"HK$2","3":"HK$3","-1":"-HK$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$1.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.97,1.0492307692307692,1.1284615384615384,1.2076923076923076,1.2869230769230768,1.366153846153846,1.4453846153846155,1.5246153846153847,1.603846153846154,1.6830769230769231,1.7623076923076924,1.8415384615384616,1.9207692307692308,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.97,1.03,1.09,1.15,1.21,1.27,1.33,1.3900000000000001,1.45,1.51,1.57,1.63,1.69,{"y":1.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.97,1.0107692307692306,1.0515384615384615,1.0923076923076922,1.133076923076923,1.1738461538461538,1.2146153846153847,1.2553846153846153,1.2961538461538462,1.3369230769230769,1.3776923076923078,1.4184615384615384,1.459230769230769,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.933,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.102,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.291,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.509,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.97,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >